NCT04693468 2026-03-13
Talazoparib and Palbociclib, Axitinib, or Crizotinib for the Treatment of Advanced or Metastatic Solid Tumors, TalaCom Trial
M.D. Anderson Cancer Center
Phase 1 Recruiting
Clinical Trials
19 trialsNCT03968406 2026-03-11
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
M.D. Anderson Cancer Center
Phase 1 Recruiting
NCT04170946 2026-03-05
Talazoparib
University Health Network, Toronto
Phase 1 Recruiting
NCT04511039 2026-03-02
Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer
Roswell Park Cancer Institute
Phase 1 Recruiting
NCT03974217 2026-02-25
Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05101551 2025-05-29
PARPAML
Stanford University
Phase 1 Recruiting
NCT04846478 2025-04-17
Phase Ia/Ib Talazoparib + Tazemetostat for mCRPC
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05053854 2025-02-20
PARLuNET
Peter MacCallum Cancer Centre, Australia
Phase 1 Recruiting
NCT04703920 2025-01-23
Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer
University of Michigan Rogel Cancer Center
Phase 1 Completed
NCT04207190 2024-11-01
Talazoparib and Gemtuzumab Ozogamicin for the Treatment of CD33 Positive Relapsed or Refractory Acute Myeloid Leukemia
Roswell Park Cancer Institute
Phase 1 Completed
NCT06218628 2024-05-03
Pacritinib w/ Talazoparib in Pts w/ Myeloproliferative Neoplasms Unresponsive to JAK2 Inhibition
Fox Chase Cancer Center
Phase 1 Recruiting
NCT04134884 2024-03-22
Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer
Indiana University
Phase 1 Completed
NCT05425862 2023-12-11
REPAIR
Peter MacCallum Cancer Centre, Australia
Phase 1 Suspended
NCT04598321 2023-10-12
BrUOG 390: Neoadjuvant Treatment With Talazoparib
Brown University
Phase 1 Terminated
NCT03426254 2023-03-29
Comparison of Safety and Clinical Benefit of Injections Subcutaneously Talazoparib Versus Oral Talazoparib in Patients With Solid Tumors
Center Trials & Treatment
Phase 1 Withdrawn
NCT02049593 2022-09-26
PARP Inhibitor BMN-673 and Temozolomide or Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Jonsson Comprehensive Cancer Center
Phase 1 Completed
NCT02392793 2021-02-09
Talazoparib Plus Irinotecan With or Without Temozolomide in Children With Refractory or Recurrent Solid Malignancies
St. Jude Children's Research Hospital
Phase 1 Completed
NCT02358200 2020-01-10
Study of BMN-673 With Carboplatin and Paclitaxel in Patients With Advanced BRCA-mutated Solid Tumor or Triple Negative Metastatic Breast Cancer
University of California, San Francisco
Phase 1 Terminated
NCT02537561 2016-02-11
Talazoparib in Combination With Gemcitabine and Cisplatin in Patients With Advanced Solid Tumors
Washington University School of Medicine
Phase 1 Withdrawn